Forming a National Strategy for the Rising Costs of Rare-Disease PharmaceuticalsRichard NaumanFeb 28, 20221 min readWritten by: Keiran Pace
The Evolution of GLP-1 Receptor Agonists: From Diabetes Treatment toNext-Generation Metabolic TherapiesQueens Pharmaceutical Sciences Research Director Cullan Wheeler Research Executives Elena Rastani and Momena Hasnain Editors Ava Ditiero and Emily Kim October 19th, 2026 GLP-1 receptor agonists have b
Comments